Poxel News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.06.22	Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting (Businesswire)
09.06.22	Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041 (Businesswire)
31.05.22	Poxel Announces its Participation in Upcoming Investor and Scientific Conferences (Businesswire)
17.05.22	Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022 (Businesswire)
17.05.22	Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy (Businesswire)
13.05.22	Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022 (Businesswire)
04.05.22	Poxel Announces Availability of Its 2021 Universal Registration Document (Businesswire)
25.04.22	Poxel Announces Its Participation in Upcoming Scientific Conferences (Businesswire)
11.04.22	Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy (Businesswire)
22.03.22	Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update (Businesswire)
15.03.22	Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022 (Businesswire)
16.02.22	Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy (Businesswire)
16.02.22	Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update (Businesswire)
04.01.22	Poxel Announces Financial Calendar for 2022 (Businesswire)
25.06.21	Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021 (Businesswire)
24.06.21	Poxel Announces Results from June 23, 2021 Ordinary Annual and Extraordinary General Meeting (Businesswire)
23.06.21	Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan (Businesswire)
19.05.21	Poxel Announces Participation at Upcoming Virtual Investor Conferences in June (Businesswire)
19.05.21	Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021 (Businesswire)
11.05.21	Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society (Businesswire)
29.04.21	Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit (Businesswire)
21.04.21	Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 (Businesswire)
24.03.21	Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update (Businesswire)
12.02.21	Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update (Businesswire)
14.01.21	Poxel Regains Imeglimin Rights From Metavant (Businesswire)
05.01.21	Poxel Announces Financial Calendar for 2021 (Businesswire)
17.12.20	Poxel Announces Participation at Upcoming Virtual Investor Conferences (Businesswire)
30.11.20	Poxel to Host Virtual NASH Investor Event with Leading Experts on December 14, 2020 (Businesswire)
20.11.20	Poxel Provides Update on Metavant Partnership with Imeglimin (Businesswire)
16.11.20	Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020 (Businesswire)
09.11.20	Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020 (Businesswire)
27.10.20	Poxel Announces Participation at Several Upcoming Scientific and Investor Conferences (Businesswire)
20.10.20	Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020 (Businesswire)
15.10.20	Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government (Businesswire)
01.10.20	Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator (Businesswire)
24.09.20	Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting (Businesswire)
21.09.20	Poxel Announces Participation at Upcoming Scientific and Investor Conferences (Businesswire)
15.09.20	Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update (Businesswire)
03.09.20	Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020 (Businesswire)
02.09.20	Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients (Businesswire)
30.07.20	Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma (Businesswire)
25.06.20	Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting (Businesswire)
24.06.20	Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
25.05.20	Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases (Businesswire)
21.04.20	Poxel Announces First Quarter 2020 Financial and Corporate Update (Businesswire)
20.04.20	Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics (Businesswire)
20.04.20	Poxel Announces Availability of 2019 Universal Registration Document and Provides Business Update (Businesswire)
26.03.20	Poxel Reports Financial Results for Full Year 2019 and Provides Corporate Update (Businesswire)
23.03.20	Poxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm EDT (Businesswire)
04.03.20	Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Poxel SA

Aktien Top/Flop

Meistgelesene Nachrichten